The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
UConn TIP company ImSTEM Biotechnology is conducting a clinical trial to test their experimental human embryonic stem cell-derived mesenchymal stem cell therapy for the treatment of multiple sclerosis.
Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS. ImStem’s investigational MSC candidate IMS001 is to be considered for further development in COVID19 and ARDS from other causes.
The FDA has lifted the clinical hold and cleared the investigational new drug (IND) application to assess IMS001 in the treatment of multiple sclerosis (MS).
The FDA has lifted the clinical hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS).